Evidence map›Paper›PMID 34981057›Full record

ArticlebioRxiv : the preprint server for biology2021

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster.

Sabrina Lusvarghi, Simon D Pollett, Sabari Nath Neerukonda, Wei Wang, Richard Wang, Russell Vassell, Nusrat J Epsi, Anthony C Fries, Brian K Agan, David A Lindholm and 20 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 43 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 12 institutions in 1 country.

Sabrina LusvarghiDivision of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Simon D PollettInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Sabari Nath NeerukondaDivision of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Wei WangDivision of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Richard WangDivision of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Russell VassellDivision of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Nusrat J EpsiInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Anthony C FriesU.S. Air Force School of Aerospace Medicine, Wright-Patterson, OH, USA.
Brian K AganInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
David A LindholmBrooke Army Medical Center, Joint Base San Antonio-Fort Sam Houston, TX, USA.
Christopher J ColomboDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Rupal ModyWilliam Beaumont Army Medical Center, El Paso, TX, USA.
Evan C EwersFort Belvoir Community Hospital, Fort Belvoir, VA, USA.
Tahaniyat LalaniInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Anuradha GanesanInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Emilie GoguetHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
Monique Hollis-PerryClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD, USA.
Si'Ana A CogginsHenry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
Mark P SimonsInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Leah C KatzelnickViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Gregory WangClinical Trials Center, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD, USA.
David R TribbleInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Lisa BentleyOffice of the Assistance Secretary for Preparedness and Response, U.S. Department of Human Health and Services, Washington D.C., USA.
Ann E EakinDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, Maryland, USA.
Christopher C BroderDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Karl J ErlandsonInfluenza and Emerging Infectious Diseases Division, Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services, Washington, D.C., USA.
Eric D LaingDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Timothy H BurgessInfectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Edward MitreDepartment of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
Carol D WeissDivision of Viral Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Henry M. Jackson Foundation · USCenter for Biologics Evaluation and Research · USUniformed Services University of the Health Sciences · USNational Institutes of Health · USNaval Medical Research Command · USAlexander T. Augusta Military Medical Center · USBiomedical Advanced Research and Development Authority · USBrooke Army Medical Center · USMadigan Army Medical Center · USOffice of Readiness and Response · USUnited States Air Force · USWilliam Beaumont Army Medical Center · US

Funding

DATA CENTER FOR EPIDEMIOLOGIC INVESTIGATIONS OF HIVN01AI005072 · NIAID · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI MCKINLAY, SONJA M · 1990 to 1994
–
NIAID NIH HHS Y01 AI005072
6 · The paper itself

Abstract

The rapid spread of the highly contagious Omicron variant of SARS-CoV-2 along with its high number of mutations in the spike gene has raised alarm about the effectiveness of current medical countermeasures. To address this concern, we measured neutralizing antibodies against Omicron in three important settings: (1) post-vaccination sera after two and three immunizations with the Pfizer/BNT162b2 vaccine, (2) convalescent sera from unvaccinated individuals infected by different variants, and (3) clinical-stage therapeutic antibodies. Using a pseudovirus neutralization assay, we found that titers against Omicron were low or undetectable after two immunizations and in most convalescent sera. A booster vaccination significantly increased titers against Omicron to levels comparable to those seen against the ancestral (D614G) variant after two immunizations. Neither age nor sex were associated with differences in post-vaccination antibody responses. Only three of 24 therapeutic antibodies tested retained their full potency against Omicron and high-level resistance was seen against fifteen. These findings underscore the potential benefit of booster mRNA vaccines for protection against Omicron and the need for additional therapeutic antibodies that are more robust to highly mutated variants. ONE SENTENCE SUMMARY: Third dose of Pfizer/BioNTech COVID-19 vaccine significantly boosts neutralizing antibodies to the Omicron variant compared to a second dose, while neutralization of Omicron by convalescent sera, two-dose vaccine-elicited sera, or therapeutic antibodies is variable and often low.

Identifiers

PMID34981057
PMCPMC8722594
OpenAlexW4200406606

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.